Hydroxychloroquine with or without azithromycin and in-hospital mortality or discharge in patients hospitalized for COVID-19 infection: a cohort study of 4,642 in-patients in France
et al., medRxiv, doi:10.1101/2020.06.16.20132597 (Preprint)
, Hydroxychloroquine with or without azithromycin and in-hospital mortality or discharge in patients.., medRxiv, doi:10.1101/2020.06.16.20132597 (Preprint)
Retrospective of 4,642 hospitalized patients in France showing significantly faster discharge with HCQ and HCQ+AZ. No significant effect is seen on 28-day mortality, however many more control patients are still in hospital at 28 days. Other studies show faster resolution for HCQ, suggesting there will be a significant improvement when extending past 28 days. Hopefully authors will extend the analysis. Note that the median age is higher in the group not treated with HCQ or AZ.For other issues with the adjustments see [medrxiv.org]. Also see the analysis here [twitter.com].
This study is excluded in the after exclusion results of meta
analysis:
significant issues found with adjustments.
|
risk of death, 5.0% higher, RR 1.05, p = 0.74, treatment 111 of 623 (17.8%), control 830 of 3,792 (21.9%), adjusted per study, whole population HCQ AIPTW adjusted.
|
|
risk of no hospital discharge, 20.0% lower, RR 0.80, p = 0.002, treatment 623, control 3,792, adjusted per study, inverted to make RR<1 favor treatment, whole population HCQ AIPTW adjusted.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Sbidian et al., 19 Jun 2020, retrospective, database analysis, France, preprint, 21 authors.
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2020.06.16.20132597; this version posted June 19, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .
Hydroxychloroquine with or without azithromycin and in-hospital mortality or discharge
in patients hospitalized for COVID-19 infection: a cohort study of 4,642 in-patients in
France
Emilie Sbidian,1,2,3* Julie Josse,4,5* Guillaume Lemaitre,6 Imke Meyer,7 Mélodie Bernaux,8
Alexandre Gramfort,4 Nathanaël Lapidus,9 Nicolas Paris,10 Antoine Neuraz,11,12 Ivan Lerner,11,12
Nicolas Garcelon,11,13 Bastien Rance,11,14 Olivier Grisel,4 Thomas Moreau,4 Ali Bellamine,10
Pierre Wolkenstein,2 Gaël Varoquaux,4 Eric Caumes,15,16 Marc Lavielle,4,5 Armand Mekontso
Dessap,17 Etienne Audureau18,19
On behalf of AP-HP/Universities/Inserm COVID-19 research collaboration ; AP-HP Covid CDR
Initiative and ‘Entrepôt de Données de Santé’ AP-HP consortium
Author Affiliations :
1- University Paris Est Creteil, Reserach unit EpiDermE, Creteil, France
2- AP-HP, Henri-Mondor hospital, Department of Dermatology, Creteil, France
3- INSERM, Centre d'Investigation Clinique 1430, Créteil, France
4- Department of Statistics INRIA, Saclay Paris Sud University, France;
5- Ecole Polytechnique, Palaiseau, France
6- Parietal, Inria Saclay, Palaiseau, France
7- EHESS (Ecole des Hautes études en sciences sociales)
8- Strategy and transformation department, APHP Greater Paris University Hospital
9- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé
Publique IPLESP, AP-HP. Sorbonne Université, Public Health Department, SaintAntoine Hospital, Paris, France.
10- WIND Department APHP Greater Paris University Hospital
11- INSERM, UMRS 1138, Cordeliers research center, Sorbonne Université, Paris, France
12- Département d’informatique médicale, Hôpital Necker-Enfants Malades, Assistance
Publique - Hôpitaux de Paris (AP-HP), F-75015 Paris, France
13- Institut Imagine, Université Paris Descartes - Université de Paris, F-75015 Paris, France
14- Département d’informatique médicale, Hôpital Européen Georges Pompidou, Assistance
Publique - Hôpitaux de Paris (AP-HP), F-75015 Paris, France
15- APHP, Hôpitaux Universitaires Pitié Salpêtrière-Charles Foix, Infectious Diseases
department, Paris, France.
16- Sorbonne Université, Institut National de la Santé et de la Recherche Médicale
(INSERM), Institut Pierre-Louis d'Epidémiologie et de Santé Publique, Paris, France
17- Medical Intensive Care Unit, Henri Mondor Hospital, Créteil, France.
18- Inserm U955, Université Paris Est Créteil (UPEC), Institut Mondor de Recherche
Biomédicale (IMRB), équipe CEpiA (Clinical Epidemiology and Ageing), Créteil, France
19- AP-HP, Henri-Mondor hospital, Department of Public Health, Clinical Research Unit,
Creteil, France
*equally contributed
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
1
medRxiv preprint doi: https://doi.org/10.1101/2020.06.16.20132597; this version posted June 19, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .
Corresponding author: E..
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.